Authors
Mark Jesus M Magbanua, L Brown Swigart, H-T Wu, Gillian L Hirst, Christina Yau, Denise M Wolf, Antony Tin, Raheleh Salari, Svetlana Shchegrova, Hemant Pawar, Amy L Delson, Angela DeMichele, Minetta C Liu, A Jo Chien, D Tripathy, S Asare, C-HJ Lin, P Billings, A Aleshin, H Sethi, M Louie, B Zimmermann, LJ Esserman, LJ van‘t Veer
Publication date
2021/2/1
Journal
Annals of Oncology
Volume
32
Issue
2
Pages
229-239
Publisher
Elsevier
Description
Background
Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is strongly associated with favorable outcome. We examined the utility of serial circulating tumor DNA (ctDNA) testing for predicting pCR and risk of metastatic recurrence.
Patients and methods
Cell-free DNA (cfDNA) was isolated from 291 plasma samples of 84 high-risk early breast cancer patients treated in the neoadjuvant I-SPY 2 TRIAL with standard NAC alone or combined with MK-2206 (AKT inhibitor) treatment. Blood was collected at pretreatment (T0), 3 weeks after initiation of paclitaxel (T1), between paclitaxel and anthracycline regimens (T2), or prior to surgery (T3). A personalized ctDNA test was designed to detect up to 16 patient-specific mutations (from whole-exome sequencing of pretreatment tumor) in cfDNA by ultra-deep sequencing. The median follow-up time for survival analysis was 4.8 years.
Results
At T0, 61 of …
Scholar articles
MJM Magbanua, LB Swigart, HT Wu, GL Hirst, C Yau… - Annals of Oncology, 2021